Nasal spray flu vaccine candidate based on UW–Madison technology shows promise when administered alongside high dose annual shot

By Will Cushman, UW News

A unique influenza vaccine candidate that’s inhaled and based on technology developed by University of Wisconsin–Madison researchers is safe and could bolster protection against seasonal and pandemic influenza for people vulnerable to severe disease when they receive it in addition to the annual flu shot.

Those are the results of a randomized, controlled trial of the vaccine candidate, administered in nasal spray form in conjunction with the annual shot to a group of 65- to 85-year-olds in 2022. The findings were recently reported in the journal Lancet Infectious Diseases. Here are the details: Read more…